<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03178591</url>
  </required_header>
  <id_info>
    <org_study_id>MED-2559-04116</org_study_id>
    <nct_id>NCT03178591</nct_id>
  </id_info>
  <brief_title>Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor</brief_title>
  <official_title>Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor on Ischemic Burden in Stable Ischemic Heart Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 2 diabetes mellitus (type 2 DM) is an important disease with increasing prevalence
      worldwide. More than 60% of diabetes patients die of CVD. Diabetes is associated with 2-to 4-
      fold increase in the risk of coronary artery disease (CAD). Diabetes patients with stable
      ischemic heart disease may have more prevalent of asymptomatic ischemia or silent ischemia
      due to autonomic neuropathy. Therefore, detection of total myocardial ischemia including both
      symptomatic and silent ischemia using ambulatory electrocardiogram monitoring may provide
      better accuracy in ischemic burden and prognosis in diabetes patients. DDP-4 inhibitors have
      favorable effects on atherosclerotic risk factors beyond glycemic control. Furthermore, DPP-4
      inhibitors may have favorable effects on ischemic preconditioning in patients with CAD. For
      this study we aim to compare the effects of between vildagliptin and Dapagliflozin on
      ischemic burden defined by total ischemic time, markers of autonomic function, biomarkers of
      myocardial injury and biomarkers of inflammation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who has ST segment depression in ambulatory ECG monitoring during 24 hours at 6 months between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of myocardial dysfunction which verified by Exercise stress test at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The event of autonomic dysfunction from heart rate variability, heart rate turbulence, QT interval at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The myocardial injury event which verified by hsTnT level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The inflammation event which verified by hsCRP, IL-6 and TNF-alpha level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The oxidative stress event which verified by MDA and 8-isoprostaglandin F2 alpha level at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The ventricular wall stretch event which verified by N-terminal ProBNP level between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The average of systolic blood pressure at 6 month between DPP4 inhibitor (vildaglptin) group and SGLT2 inhibitors (Dapagliflozin) group.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Ischemic Heart Disease</condition>
  <arm_group>
    <arm_group_label>vildagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vildagliptin is a dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) Dose of Vildagliptin is 50 mg once or twice daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin is a sodium glucose cotransporter-2 (SGLT-2 inhibitor) Dose of Dapagliflozin is 10 mg once daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vildagliptin</intervention_name>
    <arm_group_label>vildagliptin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (age &gt; 21), male or non-child bearing potential female

          2. Inadequately controlled type 2 diabetes with at least half maximum dose of metformin
             (HbA1C &gt; 6.5 and &lt; 9.0%)

          3. Stable documented CAD defined as the followings:

               1. Stable angina with &gt; 70% stenosis of at least one major epicardial artery from
                  coronary angiogram (CAG) or coronary CTA

               2. Post myocardial infarction (&gt; 30 days)

        Exclusion Criteria:

          1. Significant renal function (eGFR &lt; 30ml/min)

          2. Significant hepatic impairment or ALT/AST elevations beyond X2 upper normal limit or
             known hepatic failure

          3. Planned coronary intervention or planed surgical intervention (PCI or CABG)

          4. Recent (&lt;30 day) acute coronary syndrome (ACS)

          5. Hypersensitivity to either of the study drug components

          6. History of lactic acidosis

          7. Type 1 diabetes

          8. Current HbA1c &gt;9%

          9. Current Insulin treatment

         10. Active treatment with GLP-1 or other DPP4i medication

         11. Inability to comply with study protocol

         12. Active malignancy other than basal cell carcinoma

         13. Clinically advanced congestive heart failure - NYHA III-IV

         14. Severe left ventricular dysfunction (LVEF&lt;25%)

         15. Recent heart failure decompensation (&lt;3 months)

         16. Chronic inflammation (i.e. inflammatory bowel disease, lupus, inflammatory arthritis,
             rheumatoid arthritis) or chronic infection (i.e. chronic diabetic foot infection)

         17. Pregnancy, lactation or child-bearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arintaya Phrommintikul, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Chiang Mai University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arintaya Phrommintikul, MD</last_name>
    <phone>+66 5393 6716</phone>
    <email>arintaya.p@cmu.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Siriluck Gunaparn, RN</last_name>
    <phone>+66 5393 6716</phone>
    <email>siriluck.g@cmu.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Chiang Mai University</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arintaya Phrommintikul, MD</last_name>
      <phone>+66 5393 6716</phone>
      <email>arintaya.p@cmu.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Siriluck Gunaparn, RN</last_name>
      <phone>+66 5393 6716</phone>
      <email>siriluck.g@cmu.ac.th</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 5, 2017</last_update_submitted>
  <last_update_submitted_qc>June 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Arintaya Phrommintikul</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vildagliptin</mesh_term>
    <mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

